Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Conditions
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Mantle Cell Lymphoma
- B-cell Prolymphocytic Leukemia
- Diffuse Large Cell Lymphoma
Interventions
- BIOLOGICAL: PCAR-019 (anti-CD19 CAR-T cells)
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators